RESUMEN
Objective:To observe clinical therapeutic effect of fasudil hydrochloride in patients with chronic heart failure (CHF).Methods: A total of 134 CHF cases were selected from our department.According to random number table, they were randomly and equally divided into routine treatment group and fasudil group, both groups were treated for three months.Left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDd), left ventricular end-systolic dimension (LVESd), levels of brain natriuretic peptide (BNP), endothelin (ET)-1 and atrial natriuretic peptide (ANP) were compared between two groups before and after treatment.Results: Compared with fasudil group before treatment and routine treatment group after treatment, there were significant reductions in LVEDd [(58.20±8.44) mm, (58.22±10.21)mm vs.(51.24±7.37)mm], LVESd [(47.52±6.51) mm, (47.56±6.54)mm vs.(41.24±5.33)mm], levels of BNP [(381.35±62.48) μg/L, (377.82±61.46) μg/L vs.(294.52±51.33) μg/L], ET-1 [(81.93±13.53) μg/L, (81.32±12.63) μg/L vs.(68.44±11.42) μg/L] and ANP [(215.33±39.72) μg/L, (210.51±36.17) μg/L vs.(172.26±27.54) μg/L], and significant rise in LVEF [(29.69±4.08)%, (29.94±4.25)% vs.(37.47±5.26)%] in fasudil group after three-month treatment, P0.05.Conclusion:Fasudil hydrochloride can significantly reduce levels of BNP, ET-1 and ANP, delay ventricular remodeling and improve cardiac function in CHF patients.The therapeutic effect is significant and safety is good.